



Jagsonpal Pharmaceuticals Ltd

Corporate Office: Plot No. 412-415, Nimai Tower, 3rd Floor, Phase-IV, Udyog Vihar,
Sector-18, Gurugram -122015, Haryana (India)

Ph.: +91 124 4406710; **E-mail:** info@jagsonpal.com; **Website:** www.jagsonpal.com

CIN. : L74899DL1978PLC009181



June 29, 2026

The Department of Corporate Services- Listing BSE Ltd, Phiroze Jeejeebhoy Towers, Dalal Street Mumbai-400 001 Scrip Code: 507789	The Department of Corporate Services- Listing National Stock Exchange of India Ltd Exchange Plaza, C-1, Block G, Bandra Kurla Complex, Bandra (E) Mumbai – 400 051 Symbol: JAGSNPHARM
---------------------------------------------------------------------------------------------------------------------------------------------------------------	--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Subject: Press Release on acquisition of Aequitas Healthcare Private Limited

Dear Sir/ Madam,

Please find enclosed herewith a copy of the Press Release relating to acquisition of Aequitas Healthcare Private Limited.

We request you to take the above on record.

Thanking you,

Yours faithfully,

For **Jagsonpal Pharmaceuticals Limited**

Pratham Rawal

Company Secretary & Compliance Officer



Jagsonpal Pharmaceuticals to acquire 85% stake in Aequitas Healthcare Transaction marks its strategic entry in the Hospital segment

Gurugram, India | June 29, 2026 – Jagsonpal Pharmaceuticals Ltd. (Jagsonpal) today announced that it has entered into a definitive Agreement for the acquisition of 85% equity stake in Aequitas Healthcare Private Limited ("Aequitas"), a Mumbai-based pharmaceutical company primarily focused on sale and distribution of pharmaceutical products to hospitals.

The proposed acquisition marks Jagsonpal's strategic entry into the hospital segment and is aligned with the Company's long-term vision of strengthening its presence in India's growing healthcare ecosystem.

Founded in 2017, Aequitas has a robust business covering all leading hospital chains in India. The company had revenues of Rs. 53 crores in FY26

The total consideration for 85% stake would be Rs. 20.8 crores, which shall be funded from internal accruals of Jagsonpal. The current Directors of Aequitas shall retain 15% stake and shall continue to be associated with the business.

Commenting on the acquisition, Manish Gupta, Managing Director, Jagsonpal stated: *"The proposed acquisition of Aequitas represents an important strategic milestone for Jagsonpal. It provides us with a ready platform for a meaningful presence in the hospital segment, which now contributes ~10% of pharma industry sales and growing faster. We strongly believe that Jagsonpal's portfolio of established brands will greatly benefit from Aequitas' strong institutional relationships, delivering sustainable long-term value to our shareholders."*

Mr. Amrut Medhekar, Chief Operating Officer, Jagsonpal stated: *"This transaction is a structurally transformative pivot that moves Jagsonpal from a legacy retail prescription player to Omnichannel Specialty healthcare business in India and is reflective of our long-term commitment to building scalable, high-quality healthcare delivery in India. We look forward to unlocking value through operational excellence, disciplined execution, and patient-centric growth."*

Mr. Shailesh Kamat, Director and largest shareholder at Aequitas said: *"In a short span of 8 years, we have built a strong hospital business with a quality portfolio, deep institutional relationships and a committed team. We are pleased to associate with Jagsonpal Pharmaceuticals, whose proven track record of building healthcare brands and scaling businesses makes us well positioned to take Aequitas to its next phase of growth. We believe this partnership will unlock new opportunities for our employees, customers & stakeholders and deeply benefit the healthcare ecosystem."*

The transaction is subject to the fulfilment of customary closing conditions, and expected to be concluded by 15th July, 2026.

J Sagar & Associates were the legal Advisors to Jagsonpal while Noverra Partners advised Aequitas on the transaction.

ABOUT JAGSONPAL PHARMACEUTICALS LIMITED

Jagsonpal Pharmaceuticals Limited is a leading pharmaceutical company with a proven track record of over five decades in the Indian pharmaceutical market.

The Company has a robust portfolio of drugs focusing on Gynaecology, Orthopaedics, and Dermatology segments. Over the years, the Company has successfully built multiple brands that today hold market-leading positions in their respective segments. It has created a strong niche for itself with 20+ brands amongst Top 5 brands in the molecule category, extensive pan-India presence and an experienced sales team of over 1000 professionals.

The company is listed on the National Stock Exchange Limited (JAGSNPHARM) and Bombay Stock Exchange (Scrip code: 507789) and is headquartered in Delhi.

For more information, please visit: www.jagsonpal.com

Company contact	Investor Relations Team
Email: cs@jagsonpal.com , Tel: +91 124 4406710 Jagsonpal Pharmaceuticals Limited CIN: L74899DL1978PLC009181 Registered Office: Innov8, 3rd Floor, Plot No. 211, Okhla Phase-3, New Delhi-110020 Corporate Office: Nimai Tower, 3 rd floor, Udyog Vihar, Gurugram, Haryana – 122015	Soumya Chhajed Email- soumya@goindiaadvisors.com Mobile: +91-8619707750